Underperformance of clinical risk scores in identifying imaging-based high cardiovascular risk in psoriasis: results from two observational cohorts.


Journal

European journal of preventive cardiology
ISSN: 2047-4881
Titre abrégé: Eur J Prev Cardiol
Pays: England
ID NLM: 101564430

Informations de publication

Date de publication:
30 03 2022
Historique:
received: 03 06 2020
revised: 17 07 2020
accepted: 27 07 2020
pubmed: 25 2 2021
medline: 2 4 2022
entrez: 24 2 2021
Statut: ppublish

Résumé

We aimed to evaluate whether traditional risk scores [short-term, 'psoriasis-modified' (multiplied by 1.5) and lifetime] were able to capture high cardiovascular disease (CVD) risk as defined by the presence of atherosclerotic plaques in coronary, femoral, or carotid arteries in psoriasis. We used two prospectives obseravational cohorts. European cohort: femoral and carotid atherosclerotic plaques were evaluated by ultrasound in 73 psoriasis patients. Lifetime CVD risk (LTCVR) was evaluated with QRISK-LT; short-term CVD risk was evaluated with SCORE and psoriasis-modified SCORE. American cohort: 165 patients underwent coronary computed tomography angiography to assess presence of coronary plaques. LTCVR was evaluated with atherosclerotic cardiovascular disease (ASCVD-LT) lifetime; short-term CVD risk was evaluated with ASCVD and psoriasis-modified ASCVD. European cohort: subclinical atherosclerosis was present in 51% of patients. QRISK-LT identified 64% of patients with atherosclerosis missing a high proportion (35%) with atheroma plaque (P < 0.05). The percentage of patients with atherosclerosis identified by QRISK-LT was significantly higher than those detected by SCORE (0%) and modified SCORE (10%). American cohort: subclinical atherosclerosis was present in 54% of patients. ASCVD-LT captured 54% of patients with coronary plaques missing a high proportion (46%) with coronary plaque (P < 0.05). The percentage of patients with atheroma plaques detected with ASCVD and modified ASCVD were only 20% and 45%, respectively. Application of lifetime, short-term and 'psoriasis-modified' risk scores did not accurately capture psoriasis patients at high CVD risk.

Identifiants

pubmed: 33624060
pii: 5961604
doi: 10.1093/eurjpc/zwaa033
doi:

Types de publication

Journal Article Observational Study Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

591-598

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Auteurs

Alvaro Gonzalez-Cantero (A)

Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Aarthi S Reddy (AS)

Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, 10 Center Drive, Clinical Research Center, Room 5-5140, Bethesda, MD 20892, USA.

Amit K Dey (AK)

Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, 10 Center Drive, Clinical Research Center, Room 5-5140, Bethesda, MD 20892, USA.

Jorge Gonzalez-Cantero (J)

Department of Radiology, Gregorio Marañon Hospital, Madrid, Spain.

Eric Munger (E)

Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, 10 Center Drive, Clinical Research Center, Room 5-5140, Bethesda, MD 20892, USA.

Justin Rodante (J)

Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, 10 Center Drive, Clinical Research Center, Room 5-5140, Bethesda, MD 20892, USA.

Ana I Sanchez-Moya (AI)

Department of Dermatology, Complejo Hospitalario de Toledo, Toledo, Spain.

Cristina Perez-Hortet (C)

Department of Dermatology, Complejo Hospitalario de Toledo, Toledo, Spain.

Jorge L Gonzalez-Calvin (JL)

Department of Gastroenterology, University Hospital San Cecilio, Granada, Spain.

Martin P Playford (MP)

Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, 10 Center Drive, Clinical Research Center, Room 5-5140, Bethesda, MD 20892, USA.

María G Barderas (MG)

Department of Vascular Physiopathology, Hospital Nacional de Parapléjicos (HNP), SESCAM, Toledo, Spain.

Asunción Ballester (A)

Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Natalia Jimenez-Gomez (N)

Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Pedro Jaén (P)

Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Marcus Y Chen (MY)

Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, 10 Center Drive, Clinical Research Center, Room 5-5140, Bethesda, MD 20892, USA.

Joel M Gelfand (JM)

Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.

Nehal N Mehta (NN)

Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, 10 Center Drive, Clinical Research Center, Room 5-5140, Bethesda, MD 20892, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH